Treatment as Prevention¨

B.C. researcher gets Vatican’s blessing on life-saving HIV treatment

The Pope has endorsed a Canadian researcher’s pioneering use of antiretroviral drugs as a way to treat and prevent millions of HIV infections. Julio Montaner, director of the British Columbia Centre for Excellence in HIV/AIDS, met with Pope Francis and other officials Wednesday at the Vatican to discuss extending the life-saving treatment he pioneered at

B.C. researcher gets Vatican’s blessing on life-saving HIV treatment Read More »

Pope Francis endorses pioneering work of HIV-AIDS researcher

(Vatican Radio) Pope Francis has given the ‘thumbs up’ to the ground-breaking work of a leading Argentinian-Canadian doctor who pioneered the use of Antiretroviral drugs to treat and prevent HIV infections. Dr Julio Montaner, who is director of the British Colombia Centre for Excellence in HIV-AIDS and a special advisor to the UNAIDS programme, met

Pope Francis endorses pioneering work of HIV-AIDS researcher Read More »

Combining PrEP and ART could almost eliminate HIV infection, east African study finds

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection in the HIV-negative partner, a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, yesterday has shown. This study was a first in

Combining PrEP and ART could almost eliminate HIV infection, east African study finds Read More »

The True End of AIDS

Lately, we have been hearing a lot about the end of AIDS. Not by a cure but by targeted prevention and treatment measures to reduce the spread of HIV, including treatment as prevention® (TasP®) and the reduction of community viral load, the countdown to zero (eliminating new mother-to-child transmissions), the use of PrEP, etc. Despite

The True End of AIDS Read More »

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below